Solrikitug-Based Bispecific 1
Undisclosed
PreclinicalActive
Key Facts
About Uniquity Bio
Uniquity Bio is a private, clinical-stage biotech founded in 2022 and headquartered in New York, USA. The company is building a pipeline in immunology and inflammation, anchored by its lead in-licensed asset, solrikitug (anti-TSLP mAb), which is currently in Phase 2 trials for COPD, asthma, and eosinophilic esophagitis (EoE). Backed by Blackstone Life Sciences, Uniquity combines experienced leadership with committed capital to strategically identify and advance under-explored therapeutic opportunities for patients with limited treatment options.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |